Tackling Cancer Is the Holy Grail: Isomorphic Labs' Demis Hassabis | Bloomberg Tech: Europe 09/12/25

AI-driven drug discovery is poised to transform medicine by shifting from manual, years-long research to rapid, platform-based development. Isomorphic Labs, led by Demis Hassabis, is building a generalizable engine capable of designing molecules for diverse disease areas, including oncology and immunology. By leveraging breakthroughs like AlphaFold3, the company aims to reduce discovery timelines from years to months, effectively navigating the vast molecular space that traditional methods cannot brute-force. While partnerships with pharmaceutical giants like Novartis and Eli Lilly demonstrate early success in identifying binding matter for previously "undruggable" proteins, the field faces ongoing challenges. Experts emphasize that the ultimate success of these models depends on overcoming data silos, addressing toxicity, and navigating complex regulatory pathways to ensure that AI-generated candidates safely reach clinical application.